Data as of Apr 17
| -0.29 / -0.32%|
The 16 analysts offering 12-month price forecasts for Pharmacyclics Inc have a median target of 163.50, with a high estimate of 225.00 and a low estimate of 120.00. The median estimate represents a +82.17% increase from the last price of 89.75.
The current consensus among 18 polled investment analysts is to Buy stock in Pharmacyclics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.